Viewing Study NCT05658003

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:13 PM
Ignite Modification Date: 2025-12-30 @ 5:53 AM
Study NCT ID: NCT05658003
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-22
First Post: 2022-12-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Castration-Resistant Prostate Cancer (mCRPC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Chinese adult male population View
None therapeutic agent lutetium (177Lu) vipivotide tetraxetan View
None [177Lu]Lu-PSMA-617 View
None Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer View
None rPFS View
None Prostate-specific Membrane Antigen View
None PSMA View